Cytochrome P4502D and -2C enzymes catalyze the oxidative N-demethylation of the parkinsonism-inducing substance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in rat liver microsomes

被引:14
作者
Narimatsu, S
Tachibana, M
Masubuchi, Y
Suzuki, T
机构
[1] Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Chiba University, Inage-ku, Chiba 263
关键词
D O I
10.1021/tx9500540
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We have examined the oxidative N-demethylation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a Parkinsonism-inducing neurotoxin, in liver microsomes from adult Wistar and Dark Agouti (DA) rats. The oxidation of MPTP to 4-phenyl-1,2,3,6-tetrahydropyridine (PTP) in these preparations required NADPH as a cofactor and was significantly inhibited by SKF 525-A (2 mM). MPTP N-demethylation exhibited biphasic kinetics, consistent with two enzymes, a low K-m system (K-m1, 10.0 +/- 2.2 mu M; V-max1, 0.048 +/- 0.009 nmol/(min . mg of protein)) and a high K-m system (K-m2, 1180 +/- 91 mu M; V-max2, 4.80 +/- 0.75 nmol/(min . mg of protein)). We thus employed two substrate concentrations, 5 mu M and 5 mM, for the low and high K-m system, respectively, to assay enzyme activity in subsequent experiments. The oxidation activity was significantly decreased by pretreatment of rats with phenobarbital and beta-naphthoflavone. Furthermore, marked strain (Wistar > DA) and sex (male > female) differences were observed at low (5 mu M) and high (5 mM) substrate concentrations, respectively. Reconstitution experiments with cytochrome P450BTL, which belongs to the P4502D subfamily, and P450m1 (P4502C11) demonstrated that MPTP N-demethylase occurs at concentrations of 5 mu M and 5 mM. At 5 mM the male-specific P450m1 showed a remarkably high activity, over 400-fold that of P450BTL. Polyclonal antibodies against P450BTL and P450m1 effectively suppressed the activity at the low (5 mu M) and the high (5 mM) substrate concentrations, respectively. These results suggest that, in the microsomal preparations used, MPTP N-demethylation is mainly mediated by P4502D enzyme(s) at lower substrate concentrations and by P4502C11 at higher substrate concentrations.
引用
收藏
页码:93 / 98
页数:6
相关论文
共 33 条
[1]   ANIMAL MODELING OF HUMAN POLYMORPHIC DRUG OXIDATION - THE METABOLISM OF DEBRISOQUINE AND PHENACETIN IN RAT INBRED STRAINS [J].
ALDABBAGH, SG ;
IDLE, JR ;
SMITH, RL .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1981, 33 (03) :161-164
[2]   MUTANT DEBRISOQUINE HYDROXYLATION GENES IN PARKINSONS-DISEASE [J].
ARMSTRONG, M ;
DALY, AK ;
CHOLERTON, S ;
BATEMAN, DN ;
IDLE, JR .
LANCET, 1992, 339 (8800) :1017-1018
[3]  
BARBEAU A, 1985, LANCET, V2, P1213
[4]  
CASHMAN JR, 1986, MOL PHARMACOL, V29, P163
[5]  
CHIBA K, 1988, J PHARMACOL EXP THER, V246, P1108
[6]   CHRONIC PARKINSONISM SECONDARY TO INTRAVENOUS-INJECTION OF MEPERIDINE ANALOGS [J].
DAVIS, GC ;
WILLIAMS, AC ;
MARKEY, SP ;
EBERT, MH ;
CAINE, ED ;
REICHERT, CM ;
KOPIN, IJ .
PSYCHIATRY RESEARCH, 1979, 1 (03) :249-254
[7]   MPTP, THE NEUROTOXIN INDUCING PARKINSONS-DISEASE, IS A POTENT COMPETITIVE INHIBITOR OF HUMAN AND RAT CYTOCHROME-P450 ISOZYMES (P450BUFI, P450DB1) CATALYZING DEBRISOQUINE 4-HYDROXYLATION [J].
FONNEPFISTER, R ;
BARGETZI, MJ ;
MEYER, UA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1987, 148 (03) :1144-1150
[8]   XENOBIOTIC AND ENDOBIOTIC INHIBITORS OF CYTOCHROME-P-450DBL FUNCTION, THE TARGET OF THE DEBRISOQUINE SPARTEINE TYPE POLYMORPHISM [J].
FONNEPFISTER, R ;
MEYER, UA .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (20) :3829-3835
[9]   EVALUATION OF THE INVOLVEMENT OF A MALE SPECIFIC CYTOCHROME-P-450 ISOZYME IN SENESCENCE-ASSOCIATED DECLINE OF HEPATIC DRUG-METABOLISM IN MALE-RATS [J].
FUJITA, S ;
MORIMOTO, R ;
CHIBA, M ;
KITANI, K ;
SUZUKI, T .
BIOCHEMICAL PHARMACOLOGY, 1989, 38 (22) :3925-3931
[10]  
GUENGERICH FP, 1987, MAMMALIAN CYTOCHROME, V1, P1